Overview

Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation

Status:
Not yet recruiting

Trial end date:
2024-06-25

Target enrollment:

Participant gender:

Summary

The primary purpose of this trial is to compare three different doses of FE 999302 with 250 µg OVITRELLE and 10,000 IU NOVAREL on oocyte maturity when administered as a single dose for final development of the oocytes in women undergoing controlled ovarian stimulation.

Phase:

Phase 2

Details

Lead Sponsor:

Ferring Pharmaceuticals

Treatments:

Chorionic Gonadotropin